Q/C TECHNOLOGIES, INC. — Proxy Solicitation & Information Statement 2022

Oct 26, 2022

DEFA14A 1 formdefa14a.htm

Field: Rule-Page

Field: /Rule-Page

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

| ☐ | Preliminary Proxy Statement | | --- | --- | | ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | | ☐ | Definitive Proxy Statement | | ☒ | Definitive Additional Materials | | ☐ | Soliciting Materials Pursuant to §240.14a-12 |

MyMD Pharmaceuticals, Inc. (Name of Registrant as Specified in its Charter)

N/A (Names of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (check the appropriate box):

| ☒ | No fee required | | --- | --- | | ☐ | Fee paid previously with preliminary materials | | ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Field: Page; Sequence: 2

Field: /Page

Field: Page; Sequence: 3; Options: Last

Field: /Page